Oncology Institute of Hope and Innovation

Recent papers from Oncology Institute of Hope and Innovation

1. Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2)The Lancet Haematology · 2026
2. Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialThe Lancet · 2026
3. Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II TrialJournal of Clinical Oncology · 2026
4. Total Hip Arthroplasty in the Bundled Payments for Care Improvement Advanced Model: Who Will Bust the Bundle?Journal of Orthopaedic Experience & Innovation · 2026
5. Mezigdomide, carfilzomib, and dexamethasone (MeziKd) vs carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): Results from the phase 3 SUCCESSOR-2 trial.Journal of Clinical Oncology · 2026
6. Phase 3 trial ResQ201A of nogapendekin alfa inbakicept (NAI) plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy.Journal of Clinical Oncology · 2026
7. 151TiP Phase III trial ResQ201A of NAI plus tislelizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapyESMO Open · 2026
8. Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: Analysis from the phase 2 eNRGy trial.Journal of Clinical Oncology · 2026
9. Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitorBlood · 2025
10. Improving cancer care for older adults: Updated results from a randomized clinical trial.JCO Oncology Practice · 2025
11. OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancerGynecologic Oncology · 2025
12. CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumoursBJC Reports · 2025
13. Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open‐label study ( ACE ‐ LY ‐003)British Journal of Haematology · 2024
14. Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemiaBlood · 2024
15. Abstract PO1-04-02: ACE-Breast-03: A phase 2 study of ARX788, a novel next-generation anti-HER antibody-drug conjugate in HER2-positive metastatic breast cancer patients previously treated with trastuzumab deruxtecanCancer Research · 2024
16. A systematic review of primary large cell neuroendocrine carcinoma of the prostateFrontiers in Oncology · 2024
17. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label studyAmerican Journal of Hematology · 2022
18. Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate CancerJAMA Oncology · 2022
19. Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myelomaCancer Medicine · 2021
20. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancerCancer Chemotherapy and Pharmacology · 2021